Cargando…
Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?
With the advent of immune checkpoint blockade (ICB) therapy, treatment strategies for late-stage cancers have seen a radical advancement. In this issue of the JCI, Wang et al. characterize the functional role of miR-155 in breast cancer and its potential in harnessing the efficacy of immunotherapy....
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society for Clinical Investigation
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525109/ https://www.ncbi.nlm.nih.gov/pubmed/36189796 http://dx.doi.org/10.1172/JCI163010 |